Eli Lilly vs Novo Nordisk — The GLP‑1 Market Showdown (2026 Perspective)
By One Day Advisor Editorial Team · Last updated: October 2026 · Originally published November 2025 Quick Answer: Who is winning the GLP-1 market? Eli Lilly leads Novo Nordisk in GLP-1 medicines as of the October 29, 2026 close. Lilly's market value is about $1.14 trillion ($1,279.14 a share), roughly 6.6 times Novo's $172 billion, after Q3 revenue rose 39% to $24.4 billion. Lilly reported Q3 2026 revenue of $24.4 billion, up 39% year over year, driven primarily by Mounjaro and Zepbound. Novo reports Q3 on November 4; the FDA's CagriSema decision is due in Q4 2026. Disclosures Not investment or medical advice. This article is educational. Stock prices, clinical results and regulatory timelines change quickly; see the full disclaimer . This page contains no affiliate links. Company-reported trial results are sponsor-run; we label evidence quality using the CEBM hierar...